Cargando…
Natural product preferentially targets redox and metabolic adaptations and aberrantly active STAT3 to inhibit breast tumor growth in vivo
Dysregulated gene expression programs and redox and metabolic adaptations allow cancer cells to survive under high oxidative burden. These mechanisms also represent therapeutic vulnerabilities. Using triple-negative breast cancer (TNBC) as a model, we show that compared to normal human breast epithe...
Autores principales: | Zhu, Yinsong, Yue, Peibin, Dickinson, Cody F., Yang, Justin K., Datanagan, Kyrstin, Zhai, Ning, Zhang, Yi, Miklossy, Gabriella, Lopez-Tapia, Francisco, Tius, Marcus A., Turkson, James |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726930/ https://www.ncbi.nlm.nih.gov/pubmed/36473850 http://dx.doi.org/10.1038/s41419-022-05477-2 |
Ejemplares similares
-
Discovery of Novel Azetidine Amides as Potent Small-Molecule STAT3
Inhibitors
por: Brotherton-Pleiss, Christine, et al.
Publicado: (2020) -
Novel potent azetidine-based compounds irreversibly inhibit Stat3 activation and induce antitumor response against human breast tumor growth in vivo
por: Yue, Peibin, et al.
Publicado: (2022) -
A Functional Nuclear Epidermal Growth Factor Receptor, Src and Stat3 Heteromeric Complex in Pancreatic Cancer Cells
por: Jaganathan, Soumya, et al.
Publicado: (2011) -
Identification of Purine-Scaffold Small-Molecule Inhibitors of Stat3 Activation by QSAR Studies
por: Shahani, Vijay M., et al.
Publicado: (2010) -
Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells
por: Yue, Peibin, et al.
Publicado: (2011)